Medicare Enrolled
Dr. Qi Feng, M.D.
Hematology & Oncology · Brooklyn, NY
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Feng from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Feng?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Feng
Dr. Qi Feng is a hematology & oncology specialist in Brooklyn, NY, with 17 years of NPI registration. Based on federal Medicare data, Dr. Feng performed 638 Medicare services across 206 unique beneficiaries.
Between the years covered by Open Payments, Dr. Feng received a total of $13,545 from 50 pharmaceutical and/or device companies across 472 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Feng is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 17 years in practice
▲ 638 Medicare services
$13,545 industry payments
Medicare Practice Summary
Medicare Utilization ↗638
Medicare services
Bottom 47% in NY for hematology & oncology
206
Unique beneficiaries
$73
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~38 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
364 | $72 | $150 |
| Normal saline infusion, 500 ml Administration of sterile normal saline solution through an intravenous line. This procedure involves the infusion of a 500 ml unit of the solution. |
65 | $1 | $3 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
48 | $81 | $150 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
42 | $155 | $300 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
37 | $8 | $15 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
31 | $109 | $175 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
23 | $116 | $200 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
15 | $112 | $225 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
13 | $155 | $250 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
10.2% high complexity
0.0% medium
89.8% routine
Industry Payment Transparency
Open Payments through 2024 ↗$13,545
Total received (2018-2024)
Avg $1,935/year across 7 years
Top 21% in NY for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
50
Companies
472
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$11,112 (82.0%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$1,423 (10.5%)
Other
Charitable contributions, space rental, and other categories
$1,010 (7.5%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$3,525
2023
$2,812
2022
$2,327
2021
$2,258
2020
$1,035
2019
$1,120
2018
$468
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$1,010
Astellas Pharma US Inc
$319
GlaxoSmithKline, LLC.
$309
AngioDynamics, Inc.
$260
Exelixis Inc.
$201
Janssen Biotech, Inc.
$170
Merck Sharp & Dohme LLC
$147
Incyte Corporation
$125
Daiichi Sankyo Inc.
$100
PFIZER INC.
$98
AstraZeneca Pharmaceuticals LP
$88
E.R. Squibb & Sons, L.L.C.
$83
Rigel Pharmaceuticals, Inc.
$70
Eisai Inc.
$67
SOBI, INC
$66
PUMA BIOTECHNOLOGY, INC.
$53
Mirati Therapeutics, Inc.
$44
Lilly USA, LLC
$42
Boehringer Ingelheim Pharmaceuticals, Inc.
$39
Celgene Corporation
$38
BeiGene USA, Inc.
$34
Bayer Healthcare Pharmaceuticals Inc.
$30
Takeda Pharmaceuticals U.S.A., Inc.
$29
SHIELD THERAPEUTICS INC
$25
JAZZ PHARMACEUTICALS INC.
$24
EMD Serono, Inc.
$19
GENZYME CORPORATION
$19
Agios Pharmaceuticals, Inc.
$14
Top 3 companies account for 46.5% of 2024 payments
All-time payments by company (2018-2024) ›
Novartis Pharmaceuticals Corporation
$1,175
Janssen Biotech, Inc.
$904
AstraZeneca Pharmaceuticals LP
$794
BeiGene USA, Inc.
$748
E.R. Squibb & Sons, L.L.C.
$659
Lilly USA, LLC
$646
Incyte Corporation
$516
Merck Sharp & Dohme Corporation
$489
Rigel Pharmaceuticals, Inc.
$481
Merck Sharp & Dohme LLC
$471
Astellas Pharma US Inc
$464
PFIZER INC.
$457
Amgen Inc.
$439
Abbott Laboratories
$405
GlaxoSmithKline, LLC.
$370
AngioDynamics, Inc.
$361
Celgene Corporation
$332
Exelixis Inc.
$328
Bayer HealthCare Pharmaceuticals Inc.
$320
Eisai Inc.
$311
Boehringer Ingelheim Pharmaceuticals, Inc.
$252
SOBI, INC
$249
Alexion Pharmaceuticals, Inc.
$245
Takeda Pharmaceuticals U.S.A., Inc.
$225
EISAI INC.
$201
Seagen Inc.
$144
Gilead Sciences, Inc.
$143
Sirtex Medical Inc
$134
Regeneron Healthcare Solutions, Inc.
$132
MicroVention, Inc.
$117
Janssen Pharmaceuticals, Inc
$117
Puma Biotechnology, Inc.
$106
GENZYME CORPORATION
$104
Daiichi Sankyo Inc.
$100
Acrotech Biopharma LLC
$69
Mirati Therapeutics, Inc.
$60
Bayer Healthcare Pharmaceuticals Inc.
$60
Dova Pharmaceuticals
$59
PUMA BIOTECHNOLOGY, INC.
$53
Sobi, Inc
$47
Genentech USA, Inc.
$45
EMD Serono, Inc.
$44
JAZZ PHARMACEUTICALS INC.
$44
SHIELD THERAPEUTICS INC
$25
Apellis Pharmaceuticals, Inc.
$22
SANOFI-AVENTIS U.S. LLC
$19
Vertical Pharmaceuticals, LLC
$16
TESARO, Inc.
$16
Pharmacyclics LLC, An AbbVie Company
$14
Agios Pharmaceuticals, Inc.
$14
Top 3 companies account for 21.2% of all-time payments
Associated products mentioned in payments ›
ACCRUFER · ALUNBRIG · ANGIODYNAMICS · AREXVY · Absolute Pro vascular stent system · BELEODAQ · BRUKINSA · CABLIVI · CABOMETYX · CALQUENCE · CYRAMZA · Cabometyx · DARZALEX · DIVIGEL · DOPTELET · Doptelet · ELITEK · ENHERTU · ERLEADA · EVENITY · Empaveli · Enhertu · Erleada · Fabhalta · GILOTRIF · Halaven · Hi-Torque Command guide wire · IBRANCE · IMBRUVICA · IMFINZI · IMJUDO · INLYTA · JAKAFI · JARDIANCE · JAYPIRCA · KEYTRUDA · KISQALI · KRAZATI · LENVIMA · LIBTAYO · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · MEKINIST · MONJUVI · NANOKNIFE · NERLYNX · NINLARO · Neulasta · Nplate · OJJAARA · ONUREG · OPDIVO · OPDUALAG · OXBRYTA · Omnilink Elite vascular stent system · PADCEV · PIQRAY · PYRUKYND · Phesgo · Pomalyst · REBLOZYL · RYBREVANT · Rezlidhia · SARCLISA · SCEMBLIX · SHINGRIX · SIR-Spheres Microspheres · SPRYCEL · Stivarga · Supera peripheral stent system · TABRECTA · TAGRISSO · TECENTRIQ · TUKYSA · Tavalisse · Trodelvy · ULTOMIRIS · Ultomiris · VERZENIO · VONJO · WEB Aneurysm Embolization System · XALKORI · XARELTO · XOSPATA · Xospata · Xtandi · ZEJULA · ZEPZELCA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (82%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematology & oncology specialists within 10 mi
727
Per 100K population
27.5
County median income
$78,548
Nearest hospital
MAIMONIDES MEDICAL CENTER
1.2 mi
1.2 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Feng is a mixed practice specialist, with moderate Medicare volume, with low-engagement industry engagement, with 17 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Feng experienced with hospital follow-up visit, moderate complexity?
Based on Medicare claims data, Dr. Feng performed 364 hospital follow-up visit, moderate complexity services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Feng receive payments from pharmaceutical companies?
Yes. Dr. Feng received a total of $13,545 from 50 companies across 472 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Feng's costs compare to other hematology & oncology specialists in Brooklyn?
Dr. Feng's average Medicare payment per service is $73. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Feng) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Brooklyn
Browse hematology & oncology specialists in Brooklyn ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in NY
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in NY
Which NY hematology & oncology specialists receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology